骨髓增殖性肿瘤中的血栓形成：使用全血血小板聚集研究进行风险评估和血栓预防的单中心经验。
Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis.
机构信息
Southern Sydney Haematology, St George Private Hosipital, Sydney, Australia.
Faculty of Health, Medicine & Applied Sciences, 8691University of Wollongong, Wollongong, New South Wales, Australia.
出版信息
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221117482. doi: 10.1177/10760296221117482.
Abstract
Routine use of WBPA studies enables safe and effective risk-adapted thromboprophylaxis in MPN patients, irrespective of the underlying driver mutation and their risk predicted by the IPSET- thrombosis criteria.
摘要
常规应用 WBPA 研究可使 MPN 患者安全有效地进行风险适应性抗血栓治疗，无论其潜在的驱动突变以及基于 IPSET-thrombosis 标准预测的风险如何。
相似文献
1
Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis.骨髓增殖性肿瘤中的血栓形成：使用全血血小板聚集研究进行风险评估和血栓预防的单中心经验。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221117482. doi: 10.1177/10760296221117482.
2
Molecular biomarkers of thrombosis in myeloproliferative neoplasms.骨髓增殖性肿瘤中血栓形成的分子生物标志物。
Thromb Res. 2016 Apr;140 Suppl 1:S71-5. doi: 10.1016/S0049-3848(16)30102-5.
3
How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.我如何管理骨髓增殖性肿瘤中的血栓/血栓栓塞并发症。
Hamostaseologie. 2020 Feb;40(1):47-53. doi: 10.1055/s-0040-1701474. Epub 2020 Feb 12.
4
Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.骨髓增殖性肿瘤血栓性疾病的发病机制与治疗管理。
Semin Thromb Hemost. 2019 Sep;45(6):604-611. doi: 10.1055/s-0039-1693477. Epub 2019 Aug 5.
5
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).骨髓增殖性肿瘤患者静脉血栓栓塞症的预防和管理：德国血液学和肿瘤学会（DGHO）、奥地利血液学和肿瘤学会（ÖGHO）以及血栓与止血研究学会（GTH e.V.）止血工作组的共识声明。
Ann Hematol. 2014 Dec;93(12):1953-63. doi: 10.1007/s00277-014-2224-8. Epub 2014 Oct 14.
6
Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.60 岁以下骨髓增殖性肿瘤患者的沉默性血栓形成发生率：单中心埃及研究。
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e425-e429. doi: 10.1016/j.clml.2019.05.005. Epub 2019 May 13.
7
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.骨髓增殖性肿瘤患者 P2Y(12) 途径功能缺陷的临床和实验室意义：一项初步研究。
Acta Haematol. 2013;130(3):181-7. doi: 10.1159/000348413. Epub 2013 Jun 8.
8
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.每日两次服用阿司匹林可降低阿司匹林抵抗的转化率，并有效减少骨髓增殖性肿瘤中的细胞减少。
Platelets. 2018 Nov;29(7):723-728. doi: 10.1080/09537104.2017.1361018. Epub 2017 Nov 1.
9
Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.预防骨髓增殖性肿瘤的复发性血栓栓塞症：文献复习及关注直接口服抗凝剂。
Postgrad Med. 2021 Jun;133(5):508-516. doi: 10.1080/00325481.2021.1880844. Epub 2021 Feb 9.
10
Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.骨髓增殖性肿瘤患者静脉血栓的管理和结局：来自以色列 MPN 工作组的数据。
Acta Haematol. 2021;144(4):438-445. doi: 10.1159/000511426. Epub 2020 Dec 14.
引用本文的文献
1
Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.骨髓增殖性肿瘤女性患者出血、血栓形成及妊娠相关并发症的管理：基于病例的综述，聚焦性别特异性挑战。
J Clin Med. 2025 Feb 25;14(5):1537. doi: 10.3390/jcm14051537.
2
Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.放血疗法对低危真性红细胞增多症患者生活质量的影响。
J Clin Med. 2024 Aug 22;13(16):4952. doi: 10.3390/jcm13164952.
3
A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.关于计划接受手术的骨髓增殖性肿瘤患者出血和血栓形成风险评估的综述
Cureus. 2024 Mar 12;16(3):e56008. doi: 10.7759/cureus.56008. eCollection 2024 Mar.
4
Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis.原发性血小板增多症随访期间不同部位血栓形成的发生率：系统评价和荟萃分析。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231181117. doi: 10.1177/10760296231181117.
本文引用的文献
1
Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.BCR-ABL 阴性骨髓增殖性肿瘤（MPN）的出血并发症：一项回顾性单中心 829 例 MPN 患者研究。
Eur J Haematol. 2022 Feb;108(2):154-162. doi: 10.1111/ejh.13721. Epub 2021 Nov 10.
2
Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.基于数据的动力学分析：羟基脲治疗真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化患者时 JAK2V617F 等位基因负担和血细胞计数的变化。
Eur J Haematol. 2021 Dec;107(6):624-633. doi: 10.1111/ejh.13700. Epub 2021 Sep 30.
3
The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.骨髓增殖性肿瘤中的血栓形成、微血管病和出血的病理生物学。
Blood. 2021 Apr 22;137(16):2152-2160. doi: 10.1182/blood.2020008109.
4
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.临床视角下骨髓增殖性肿瘤中血栓形成的起源。
Blood. 2021 Mar 4;137(9):1145-1153. doi: 10.1182/blood.2020008043.
5
Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia.血小板 Toll 样受体介导原发性血小板增多症患者的血栓炎症反应。
Front Immunol. 2020 Apr 30;11:705. doi: 10.3389/fimmu.2020.00705. eCollection 2020.
6
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.一项随机双盲试验，比较三种阿司匹林方案优化原发性血小板增多症的抗血小板治疗。
Blood. 2020 Jul 9;136(2):171-182. doi: 10.1182/blood.2019004596.
7
Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.突变型钙网织蛋白所致特发性血小板增多症患者的血小板比 JAK2 V617F 突变型血小板的反应性更低。
Am J Hematol. 2020 Apr;95(4):379-386. doi: 10.1002/ajh.25713. Epub 2020 Jan 8.
8
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.JAK2 在衰老、炎症、造血和恶性转化中的作用。
Cells. 2019 Aug 8;8(8):854. doi: 10.3390/cells8080854.
9
Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.费城染色体阴性骨髓增殖性肿瘤中的血栓形成
Cancer Treat Res. 2019;179:159-178. doi: 10.1007/978-3-030-20315-3_11.
10
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.骨髓增殖性肿瘤患者的动脉和静脉血栓形成风险：一项基于人群的队列研究。
Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16.
Zotero 插件